Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Zakeri, Sedigheh ^a   Motmaen, Shadi Rabiei ^a,b   Afsharpad, Mandana ^a   Djadid, Navid Dinparast ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b Khatam University   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; FANSIDAR; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FOLIC ACID ANTAGONIST;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; DHFR GENE; DHPS GENE; ENDEMIC DISEASE; GENE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; INFANT; IRAN; MAJOR CLINICAL STUDY; MALARIA; MIDDLE EAST; PARASITE ISOLATION; PLASMODIUM VIVAX; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CHEMISTRY; DNA SEQUENCE; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR GENETICS; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANIMALS; CHILD; CHILD, PRESCHOOL; DIHYDROPTEROATE SYNTHASE; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; GENOTYPE; HUMANS; INFANT; IRAN; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PLASMODIUM VIVAX; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEQUENCE ANALYSIS, DNA; TETRAHYDROFOLATE DEHYDROGENASE; YOUNG ADULT;

EID: 62149095320     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-20     Document Type: Article

References (48)

1. The neglected burden of Plasmodium vivax malaria. K Mendis BJ Sina P Marchesini R Carter, Am J Trop Med Hyg 2001 64 1-2 Suppl 97 106 1, 3 11425182
2. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. JK Baird H Basri B Subianto LC Patchen SL Hoffman, Am J Trop Med Hyg 1991 4 547 552
3. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. JK Baird B Leksana S Masbar DJ Fryauff MA Sutanihardja Suradi FS Wignall SL Hoffman, Am J Trop Med Hyg 1997 56 621 26 9230792
4. Vivax malaria resistant to chloroquine: case reports from Bombay. M Garg N Gopinathan P Bodhe NA Khirsagar, Trans R Soc Med Hyg 1995 89 656 657 10.1016/0035-9203(95)90432-8
5. Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). MP Kyaw MP Kyaw O Myint L Myint Z Thaw KH Aye NN Yin, Trans R Soc Trop Med Hyg 1993 87 687 10.1016/0035-9203(93)90294-Z 8296378
6. Vivax malaria resistant to treatment and prophylaxis with chloroquine. GS Murphy H Basri Purnomo EM Andersen MJ Bangs DL Mount J Gorden AA Lal A Purwokusumo S Harjosuwarno K Sorensen SL Hoffman, Lancet 1993 341 96 100 10.1016/0140-6736(93)92568-E 8093414
7. Plasmodium vivax resistance to chloroquine. KH Rieckmann DR Davis DC Hutton, Lancet 1989 ii 1183 1184 10.1016/S0140-6736(89)91792-3
8. Therapeutic responses to different antimalarial drugs in vivax malaria. S Pukrittayakamee A Chantra J Simpson S Vanijanonta R Clemens S Looareesuwan NJ White, Antimicrob Agents Chemother 2000 44 1680 1685 10817728 10.1128/AAC.44.6.1680-1685.2000
9. Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum. MT Alam H Bora PK Bharti MA Saifi MK Das V Dev A Kumar N Singh AP Dash B Das, Antimicrob Agents Chemother 2007 51 857 863 17194833 10.1128/AAC.01200-06
10. Sequence variations in the Plasmodium vivax dihydrofolate reductasethymidylate synthase gene and their relationship with pyrimethamine resistance. PE de Pecoulas R Tahar T Ouatas A Mazabraud LK Basco, Mol Biochem Parasitol 1998 92 265 273 10.1016/S0166-6851(97)00247-8 9657331
11. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulphadoxinee plus pyrimethamine. MD Hastings KM Porter JD Maguire I Susanti W Kania MJ Bangs CH Sibley JK Baird, J Infect Dis 2004 189 744 750 10.1086/381397 14767830
12. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulphadoxinee-pyrimethamine: geographical and clinical correlates. M Imwong S Pukrittakayamee S Looareesuwan G Pasvol J Poirreiz NJ White G Snounou, Antimicrob Agents Chemother 2001 45 3122 3127 11600366 10.1128/AAC.45.11.3122- 3127.2001
13. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. M Imwong S Pukrittayakamee L Renia F Letourneur JP Charlieu U Leartsakulpanich S Looareesuwan NJ White G Snounou, Antimicrob Agents Chemother 2003 47 1514 1521 12709316 10.1128/AAC.47.5.1514-1521.2003
14. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. SJ Foote D Galatis AF Cowman, Proc Natl Acad Sci USA 1990 87 3014 3017 2183221 10.1073/pnas.87.8.3014
15. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. DS Peterson WK Milhous TE Wellems, Proc Natl Acad Sci USA 1990 87 3018 3022 2183222 10.1073/pnas.87.8.3018
16. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. DS Peterson D Walliker TE Wellems, Proc Natl Acad Sci USA 1988 85 9114 9118 2904149 10.1073/pnas.85.23.9114
17. Therapeutic efficacies of artesunate-sulphadoxinee-pyrimethamine and chloroquinesulphadoxinee-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. E Tjitra J Baker S Suprianto Q Cheng NM Anstey, Antimicrob Agents Chemother 2002 46 3947 3953 12435700 10.1128/AAC.46.12.3947-3953.2002
18. The mode of action and the mechanism of resistance to antimalarial drugs. SJ Foote AF Cowman, Acta Trop 1994 56 157 171 10.1016/0001-706X(94)90061-2 8203302
19. Dihydrofolate reductase: X-ray structure of the binary complex with methotrexate. DA Matthews RA Alden JT Bolin ST Freer R Hamlin N Xuong J Kraut M Poe M Williams K Hoogsteen, Science 1977 197 452 455 10.1126/science.17920 17920
20. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. DS Peterson WK Milhous TE Wellems, Proc Natl Acad Sci USA 1988 85 9114 9118 2904149 10.1073/pnas.85.23.9114
21. The dihydrofolate reductase domain of Plasmodium falciparum thymidylate synthase-dihydrofolate reductase: gene synthesis, expression, and anti-folate resistance mutants. W Sirawaraporn P Prapunwattana R Sirawaraporn Y Yuthavong DV Santi, J Biol Chem 1993 268 21637 21644 8408015
22. Characterisation of the dihydrofolate reductase-thymidylate synthase gene from human malaria parasites highly resistant to pyrimethamine. VA Snewin SM England PFG Sims JE Hyde, Gene 1989 76 41 52 10.1016/0378-1119(89)90006-1 2663650
23. Pyrimethamine resistant mutations in Plasmodium falciparum. S Thaithong SW Chan S Songsomboon P Wilairat N Seesod T Sueblinwong M Goman R Ridley G Beale, Mol Biochem Parasitol 1992 52 149 158 10.1016/0166-6851(92)90047-N 1620155
24. Crystal structure of avian dihydrofolate reductase containing phenyltriazine and NADPH. KW Volz DA Matthews RA Alden ST Freer C Hansch BT Kaufman J Kraut, J Biol Chem 1982 257 2528 2536 7061437
25. The mode of action and the mechanism of resistance to antimalarial drugs. SJ Foote AF Cowman, Acta Trop 1994 56 157 171 10.1016/0001-706X(94)90061-2 8203302
26. Detection of malaria parasites by nested PCR in south-eastern, Iran: Evidence of highly mixed infections in Chabahar district. S Zakeri S Najajabadi A Zare N Djadid, Malar J 2002 1 2 12057020 10.1186/1475-2875-1-2
27. Mixed-species malaria infections in humans. M Mayxay S Pukrittayakamee PN Newton NJ White, Trends Parasitol 2004 20 233 240 10.1016/j.pt.2004.03.006 15105024
28. Random distribution of mixed species malaria infections in Papua New Guinea. RK Mehlotra K Lorry W Kastens SM Miller MP Alpers M Bockarie JW Kazura PA Zimmerman, Am J Trop Med Hyg 2000 62 225 231 10813477
29. The co-existence of Plasmodium: sidelights from falciparum and vivax malaria in Thailand. G Snounou NJ White, Trends Parasitol 2004 20 333 339 10.1016/j.pt.2004.05.004 15193565
30. Cultivation of Plasmodium vivax. R Udomsangpetch O Kaneko K Chotivanich J Sattabongkot, Trends Parasitol 2008 24 85 88 10.1016/j.pt.2007.09.010 18180202
31. Antifolates can have a role in the treatment of Plasmodium vivax. VN Hawkins H Joshi K Rungsihirunrat K Na-Bangchang CH Sibley, Trends Parasitol 2007 23 5 213 222 10.1016/j.pt.2007.03.002 17368986
32. Plasmodium vivax dhfr and dhps mutations in isolates from Madagascar and therapeutic response to sulphadoxine-pyrimethamine. C Barnadas M Tichit C Bouchier A Ratsimbasoa L Randrianasolo R Raherinjafy M Jahevitra S Picot D Menard, Malar J 2008 7 35 18302746 10.1186/1475-2875-7-35
33. Population structure analysis of Plasmodium vivax in areas of Iran with different malaria endemicity. S Zakeri AA Mehrizi S Mamaghani S Noorizadeh G Snounou ND Djadid, Am J Trop Med Hyg 2006 74 3 394 400 16525096
34. Association of pfcrt but not pfmdr1 alleles with chloroquine resistance in Iranian isolates of Plasmodium falciparum. S Zakeri M Afsharpad T Kazemzadeh K Mehdizadeh A Shabani ND Djadid, Am J Trop Med Hyg 2008 78 633 640 18385361
35. Assessment of the response in vivo and in vitro of Plasmodium falciparum to sulphadoxine-pyrimethamine in the malarious areas of Iran. GH Edrissian A Afshar A Sayedzadeh GH Mohsseni MT Satvat, J Trop Med Hyge 1993 96 237 240
36. Genotypes and in vivo resistance of Plasmodium falciparum isolates in an endemic region of Iran. A Heidari S Dittrich T Jelink A Kheirandish K Banihashemi H Keshavarz, Parasitol Res 2007 100 589 592 10.1007/s00436-006-0291- z 17024359
37. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. G Snounou S Viriyakosol XP Zhu W Jarra L Pinheiro VE do Rosario S Thaithong KN Brown, Mol Biochem Parasitol 1993 61 315 320 10.1016/0166-6851(93)90077-B 8264734
38. Limited Polymorphism in the Dihydropteroate Synthetase Gene (dhps) of Plasmodium vivax Isolates from Thailand. M Imwong S Pukrittayakamee Q Cheng C Moore S Looareesuwan G Snounou NJ White NPJ Day, Antimicrob Agents Chemother 2005 49 4393 4395 16189131 10.1128/AAC.49.10.4393-4395.2005
39. Evaluation of sensitivity of Plasmodium vivax to chloroquine. M Nateghpour SA Sayedzadeh GhH Edrissian A Raeisi A Jahantigh A Motevalli-Haghi Gh Mohseni A Rahimi, Iranian J Publ Health 2007 36 60 63
40. Kinetic properties of dihydrofolate reductase from wild-type and mutant Plasmodium vivax expressed in Escherichia coli. R Tahar PE de Pécoulas LK Basco M Chiadmi A Mazabraud, Mol Biochem Parasitol 2001 113 241 249 10.1016/S0166-6851(01)00230-4 11295178
41. Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. U Leartsakulpanich M Imwong S Pukrittayakamee NJ White G Snounou W Sirawaraporn Y Yuthavong, Mol Biochem Parasitol 2002 119 63 73 10.1016/S0166-6851(01)00402-9 11755187
42. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine- sulphadoxinee use and resistance. CV Plowe JF Cortese A Djimde OC Nwanyanwu WM Watkins PA Winstanley JG Estrada-Franco OK Doumbo, J Infect Dis 1997 176 1590 1596 9395372
43. Molecular markers for failure of sulphadoxinee-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. JG Kublin FK Dzinjalamala DD Kamwendo EM Malkin JF Cortese LM Martino RAG Mukadam SJ Rogerson AG Lescano ME Molyneux PA Winstanley P Chimpeni TE Taylor CV Plowe, J Infect Dis 2002 185 380 388 10.1086/338566 11807721
44. Towards an understanding of the mechanism of pyrimethamine-sulphadoxinee resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. AM Nzila EK Mberu J Sulo H Dayo PA Winstanley CH Sibley WM Watkins, Antimicrob Agents Chemother 2000 44 991 996 10722502 10.1128/AAC.44.4.991-996.2000
45. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. T Mutabingwa A Nzila E Mberu E Nduati P Winstanley E Hills W Watkins, Lancet 2001 358 1218 1223 10.1016/S0140-6736(01)06344-9 11675058
46. Validation of a simplified method for using molecular markers to predict sulphadoxinee-pyrimethamine treatment failure in African children with falciparum malaria. D Kyabayinze A Cattamanchi MR Kamya PJ Rosenthal G Dorsey, Am J Trop Med Hyg 2003 69 247 252 14628939
47. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. SG Staedke H Sendagire S Lamola MR Kamya G Dorsey PJ Rosenthal, Trop Med Int Health 2004 9 624 629 10.1111/j.1365-3156.2004.01239.x 15117308
48. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. A Nzila, J Antimicrob Chemother 2006 57 1043 1054 10.1093/jac/dkl104 16617066